BR102018015076A2 - extracts and bioactive compounds isolated from the bark of the jatoba stem with antihypertensive action - Google Patents
extracts and bioactive compounds isolated from the bark of the jatoba stem with antihypertensive action Download PDFInfo
- Publication number
- BR102018015076A2 BR102018015076A2 BR102018015076A BR102018015076A BR102018015076A2 BR 102018015076 A2 BR102018015076 A2 BR 102018015076A2 BR 102018015076 A BR102018015076 A BR 102018015076A BR 102018015076 A BR102018015076 A BR 102018015076A BR 102018015076 A2 BR102018015076 A2 BR 102018015076A2
- Authority
- BR
- Brazil
- Prior art keywords
- hours
- stem
- bark
- stage
- extracts
- Prior art date
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
extratos e compostos bioativos isolados da casca do caule do jatobá com ação anti-hipertensiva a presente invenção compreende a obtenção de extratos, frações e compostos isolados da casca do caule da hymenaea rubriflora ducke com aplicação no tratamento de doenças que tem o estresse oxidativo como uma de suas etiologias visando especificamente à redução da pressão arterial em hipertensos. para a obtenção do extrato, a casca do caule foi fracionada, seca em estufa por 45ºc durante 24 horas e triturada. após isso, a amostra foi submetida à extração usando como solvente etanol-água na proporção de 1:1, levada ao agitador por 4 horas em 200g e filtrada à vácuo em papel de filtro para retirada do material particulado. o extrato seco foi obtido por meio da solução extrativa que foi levada a rota evaporação a 40ºc. em seguida, o extrato livre de etanol foi congelado em freezer (- 80ºc) por 24 horas e, posteriormente, liofilizado a 0,024 mbar por 72 horas, obtendo-se, por fim, o extrato.extracts and bioactive compounds isolated from the bark of the jatobá stem with antihypertensive action the present invention comprises obtaining extracts, fractions and compounds isolated from the stem bark of hymenaea rubriflora ducke with application in the treatment of diseases that have oxidative stress as a its etiologies aiming specifically at lowering blood pressure in hypertensive patients. to obtain the extract, the stem bark was fractionated, dried in an oven for 45 hours during 24 hours and crushed. after that, the sample was subjected to extraction using ethanol-water in the proportion of 1: 1, taken to the shaker for 4 hours in 200g and vacuum filtered on filter paper to remove particulate material. the dry extract was obtained by means of the extractive solution that was taken to the evaporation route at 40ºc. afterwards, the ethanol-free extract was frozen in a freezer (- 80ºc) for 24 hours and, subsequently, lyophilized at 0.024 mbar for 72 hours, finally obtaining the extract.
Description
“EXTRATOS E COMPOSTOS BIOATIVOS ISOLADOS DA CASCA DO CAULE DO JATOBÁ COM AÇÃO ANTI-HIPERTENSIVA” [001] A presente invenção trata de obtenção de extratos, frações e compostos isolados da casca do caule da Hymenaea rubriflora Ducke, conhecida popularmente como Jatobá, com atividade anti-hipertensiva e antioxidante. Este composto é obtido por meio da maceração da casca do caule, podendo ser apresentado na forma de extrato, frações, liofilizado ou compostos bioativos isolados da casca do caule da Hymenaea rubriflora Ducke com aplicação na área de tratamento de doenças que tem o estresse oxidativo como uma de suas etiologias visando especificamente a redução da pressão arterial em hipertensos.“EXTRACTS AND BIOACTIVE COMPOUNDS ISOLATED FROM THE STRAP OF JATOBÁ STEM WITH ANTI-HYPERTENSIVE ACTION” [001] The present invention deals with obtaining extracts, fractions and compounds isolated from the stem bark of Hymenaea rubriflora Ducke, popularly known as Jatobá, with activity antihypertensive and antioxidant. This compound is obtained through maceration of the stem bark, and can be presented in the form of extract, fractions, lyophilized or bioactive compounds isolated from the stem bark of Hymenaea rubriflora Ducke with application in the area of treatment of diseases that have oxidative stress as one of its etiologies specifically aimed at lowering blood pressure in hypertensive patients.
[002] Atualmente, a terapia medicamentosa anti-hipertensiva apresenta eficácia na redução da pressão arterial, porém cada fármaco atua em apenas um determinado sistema de controle pressórico, de acordo com a classe (vasodilatadores diretos, alfabloqueadores, diuréticos, inibidores da ECA, entre outros). Desta forma, a maioria dos hipertensos necessita usar mais de um medicamento, com diferentes mecanismos de ação, para que seja atingido o adequado controle da pressão arterial, podendo eventualmente surgir efeitos adversos.[002] Currently, antihypertensive drug therapy is effective in lowering blood pressure, but each drug acts in only one specific pressure control system, according to class (direct vasodilators, alpha-blockers, diuretics, ACE inhibitors, among others). others). Thus, most hypertensive patients need to use more than one medication, with different mechanisms of action, in order to achieve adequate control of blood pressure, which may eventually lead to adverse effects.
[003] É sabido que embora eficientes medicamentos atuem no controle pressórico apenas 20 a 30% das pessoas que se tratam exclusivamente com medicamentos conseguem manter a pressão arterial controlada. Uma provável explicação é que enquanto os medicamentos atuam em apenas um mecanismo hipertensivo, a hipertensão arterial tem vários mecanismos atuando ao mesmo tempo. Esta constatação sugere que ainda são necessários o desenvolvimento de produtos de origem farmacológica ou nutracêutica com capacidade de promover redução da pressão arterial e preferencialmente que atuem em vários sistemas de controle da pressão arterial.[003] It is known that although efficient medications act on blood pressure control, only 20 to 30% of people who are treated exclusively with medications are able to keep their blood pressure under control. A probable explanation is that while drugs act on only one hypertensive mechanism, arterial hypertension has several mechanisms at the same time. This finding suggests that it is still necessary to develop products of pharmacological or nutraceutical origin with the ability to promote blood pressure reduction and preferably that act in several blood pressure control systems.
Petição 870180149716, de 09/11/2018, pág. 3/7Petition 870180149716, of 11/09/2018, p. 3/7
2/2 [004] Com o intuito de solucionar tais problemas desenvolveu-se a presente invenção, trata-se de um extrato obtido a partir da casca do caule do Hymenaea rubriflora Ducke, o qual é rico em antioxidantes, principalmente, devido à presença de compostos fenólicos. Estudos de nosso laboratório na Universidade Federal da Paraíba demonstraram que estes extrato tem apreciável ação em promover redução da pressão arterial e este fenômeno é acompanhado pela redução do estresse oxidativo, melhoria da modulação do sistema nervoso autonômico simpática/parassimpática, menor resposta contrátil em artérias de modelo animal a agentes contráteis e melhor resposta a agentes relaxantes. Assim, esta espécie arbórea, pode se apresentar como uma rica fonte de princípios ativos, e ser utilizada para produzir compostos de importância farmacológica (principalmente anti-hipertensiva), por meio da obtenção de substâncias ativas isoladas e formulação de fitoterápicos ou de medicamentos.2/2 [004] In order to solve such problems the present invention was developed, it is an extract obtained from the stem bark of Hymenaea rubriflora Ducke, which is rich in antioxidants, mainly due to the presence phenolic compounds. Studies from our laboratory at the Federal University of Paraíba have shown that these extracts have an appreciable action in promoting blood pressure reduction and this phenomenon is accompanied by the reduction of oxidative stress, improvement of the sympathetic / parasympathetic autonomic nervous system modulation, less contractile response in arteries of animal model to contractile agents and better response to relaxing agents. Thus, this tree species can present itself as a rich source of active ingredients, and can be used to produce compounds of pharmacological importance (mainly antihypertensive), by obtaining isolated active substances and formulating herbal medicines or medicines.
[005] A invenção poderá ser melhor compreendida através da seguinte descrição detalhada:[005] The invention can be better understood through the following detailed description:
[006] A obtenção do extrato do Hymenaea rubriflora Ducke compreende: 1) Coletar as cascas do caule da Hymenaea rubriflora Ducke,[006] Obtaining the extract of Hymenaea rubriflora Ducke comprises: 1) Collecting the bark of the stem of Hymenaea rubriflora Ducke,
2) Fracionar em pedações menores, 3) Secar em estufa por 45°C durante 24 horas, 4) Triturar e uniformizar as partículas, 5) Extração em temperatura ambiente usando como solvente etanol-água na proporção 1:1, 6) Agitar por 4 horas em 200g, 7) Filtrar à vácuo em papel de filtro, 8) Rota evaporar a 40°C até a redução do volume à metade do volume inicial da mistura de extração, 9) Congelar em freezer (- 80°C) por 24 horas e posteriormente liofilizar a 0,024 mBar por 72 horas, obtendo-se, por fim, o extrato seco, caracterizado como extrato hidroalcoólico da casca do caule do Hymenaea rubriflora Ducke.2) Fraction into smaller pieces, 3) Dry in an oven at 45 ° C for 24 hours, 4) Grind and uniformize the particles, 5) Extraction at room temperature using ethanol-water in a 1: 1 ratio, 6) Stir by 4 hours in 200g, 7) Filter under vacuum on filter paper, 8) Route evaporate at 40 ° C until the volume is reduced to half the initial volume of the extraction mixture, 9) Freeze in freezer (- 80 ° C) for 24 hours and then lyophilize at 0.024 mBar for 72 hours, obtaining, finally, the dry extract, characterized as hydroalcoholic extract from the stem bark of Hymenaea rubriflora Ducke.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR102018015076A BR102018015076A2 (en) | 2018-07-24 | 2018-07-24 | extracts and bioactive compounds isolated from the bark of the jatoba stem with antihypertensive action |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR102018015076A BR102018015076A2 (en) | 2018-07-24 | 2018-07-24 | extracts and bioactive compounds isolated from the bark of the jatoba stem with antihypertensive action |
Publications (1)
Publication Number | Publication Date |
---|---|
BR102018015076A2 true BR102018015076A2 (en) | 2020-02-04 |
Family
ID=69527705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR102018015076A BR102018015076A2 (en) | 2018-07-24 | 2018-07-24 | extracts and bioactive compounds isolated from the bark of the jatoba stem with antihypertensive action |
Country Status (1)
Country | Link |
---|---|
BR (1) | BR102018015076A2 (en) |
-
2018
- 2018-07-24 BR BR102018015076A patent/BR102018015076A2/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shikov et al. | Medicinal plants from the 14th edition of the Russian Pharmacopoeia, recent updates | |
Sunmathi et al. | In vitro Anti-inflammatory and antiarthritic activity of ethanolic leaf extract of Alternanthera sessilis (L.) R. BR. ex DC and Alternanthera philoxeroides (Mart.) Griseb | |
Zhang et al. | Regulative effects of essential oil from Atractylodes lancea on delayed gastric emptying in stress-induced rats | |
Singh et al. | Can protective factors inculcate molecular adaptations of cardiomyocyte in the prevention of chronic heart failure? | |
BRPI0604281A (en) | process for obtaining euterpe oleracea (açaì) fruit and stone clusters process for obtaining hydroalcoholic extracts from the cleavages; process of obtaining lyophilisate and / or spray dryer of the hydroalcoholic extract; pharmaceutical compositions containing the lyophilisates and / or spray dryers of said extracts and therapeutic use of the compositions as a vasodilator in the treatment of ischemic, vaso-spastic and arterial hypertension syndromes | |
Nöldner et al. | Inhibition of lipopolysaccharid-induced sickness behavior by a dry extract from the roots of Pelargonium sidoides (EPs® 7630) in mice | |
BR102018015076A2 (en) | extracts and bioactive compounds isolated from the bark of the jatoba stem with antihypertensive action | |
Rajendran et al. | In vitro and in vivo anti-snake venom (Daboia russelli) studies on various leaf extracts of Acalypha indica Linn | |
RU2252029C1 (en) | Curative-prophylactic composition including combinations of soybean phospholipid complex and extracts of medicinal plants, and biologically active additive based upon this composition | |
Ribeiro et al. | Anti-inflammatory and antinociceptive activities of the hydroalcoholic extract and the volatile fraction of southeastern Brazilian brown propolis | |
Girish et al. | Influence of Tinospora cordifolia on wound healing in albino rats | |
Farzan et al. | Phytotherapy for seizure: An overview of the most important indigenous Iranian medicinal plants with anticonvulsant properties | |
Lobo et al. | Preliminary study on the antisnake venom activity of alcoholic root extract of Clerodendrum viscosum (Vent.) in Naja naja venom | |
Gupta et al. | Evaluation of Prosopis cineraria (Linn.) Druce leaves for wound healing activity in rats | |
Son et al. | Antiplatelet mechanism of an herbal mixture prepared from the extracts of Phyllostachys pubescens leaves and Prunus mume fruits | |
RU2509565C2 (en) | METHOD FOR PREPARING FRACTION 4 (APD-f4) AND FRACTION 5 (APD-f5) ADAPTOGENIC DOROGOV'S PREPARATION | |
Wufem et al. | Preliminary studies on the antivenin potential and phytochemical analysis of the crude extracts of Balanites aegyptiaca (Linn.) Delile on albino rats | |
Arya et al. | In vitro hypolipidemic activity of Averrhoa bilimbi flower extract | |
US10420808B2 (en) | Seaweed extract and composition useful against cancer cells | |
US9750773B2 (en) | Factors extracted from fish embryos and use of mixtures thereof in the control of stem cell multiplication and differentiation | |
Siju et al. | In-Vitro Anti-inflammatory Activity of Fractions of Ailanthus excelsa Roxb. by HRBC Membrane Stabilization | |
Chethankumar et al. | Turmerin, a protein from Curcuma longa L. prevent oxidative organ damage against Naja naja venom phospholipase A2 in experimental animal | |
Balamurugan et al. | In-vitro Anti-Inflammatory and Anti-Arthritic Activity of Cardiospermum Halicacabum and Moringa Oleifera Leaves Extract | |
Kakade et al. | Anti-Inflammatory Approach of Cissus Quadrangularis Linn. By In-Vitro Means | |
Syrov et al. | Antiulcer activity of polyprenols extracted from cotton leaves |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |